Yu Xin, Yu Bin, Fang Weidan, Xiong Jianping, Ma Mei
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Discov Oncol. 2021 Oct 16;12(1):41. doi: 10.1007/s12672-021-00434-5.
Gastric cancer (GC) has a great fatality rate, meanwhile, there is still a lack of available biomarkers for prognosis. The goal of the research was to discover key and novel potential biomarkers for GC. We screened for the expression of significantly altered genes based on survival rates from two consensus molecular subtypes (CMS) of GC. Subsequently, functional enrichment analysis showed these genes involved in many cancers. And we picked 6 hub genes that could both secreted in the tumor microenvironment and expression enhanced in immune cells. Then, Kaplan Meier survival and expression detected in the tumor pathological stage were utilized to clarify the prognostic of these 6 hub genes. The results indicated that OGN, CHRDL2, C2orf40, THBS4, CHRDL1, and ANGPTL1, respectively, were significantly associated with poor OS in GC patients. And their expression increased with cancer advanced. Moreover, immune infiltration analysis displayed that those hub genes expression positively with M2 macrophage, CD8+ T Cell, most immune inhibitors, and majority immunostimulators. In summary, our results suggested that OGN, CHRDL2, C2orf40, THBS4, CHRDL1, and ANGPTL1 were all potential biomarkers for GC prognosis and might also be potential therapeutic targets for GC.
胃癌（GC）的致死率很高，同时，仍然缺乏可用的预后生物标志物。该研究的目的是发现GC关键且新颖的潜在生物标志物。我们基于GC的两种共识分子亚型（CMS）的生存率筛选了显著改变基因的表达。随后，功能富集分析表明这些基因与多种癌症有关。我们挑选了6个在肿瘤微环境中既能分泌又在免疫细胞中表达增强的枢纽基因。然后，利用Kaplan Meier生存分析以及在肿瘤病理阶段检测到的表达情况来阐明这6个枢纽基因的预后情况。结果表明，OGN、CHRDL2、C2orf40、THBS4、CHRDL1和ANGPTL1分别与GC患者的不良总生存期显著相关。并且它们的表达随着癌症进展而增加。此外，免疫浸润分析显示，这些枢纽基因的表达与M2巨噬细胞、CD8 + T细胞、大多数免疫抑制剂和多数免疫刺激剂呈正相关。总之，我们的结果表明，OGN、CHRDL2、C2orf40、THBS4、CHRDL1和ANGPTL1都是GC预后的潜在生物标志物，也可能是GC的潜在治疗靶点。
